RecruitingNot ApplicableNCT06288711

Novel Telemedicine-Delivered Prolonged Exposure Therapy for Treating PTSD in Individuals With OUD

Sponsor

University of Vermont

Enrollment

135 participants

Start Date

Jun 3, 2024

Study Type

INTERVENTIONAL

Conditions

Opioid-use Disorder Posttraumatic Stress Disorder

Summary

Among individuals with opioid use disorder (OUD), posttraumatic stress disorder (PTSD) presents a significant clinical challenge. The prevalence of PTSD is substantially higher in individuals with OUD than in the general population, with nearly 90% reporting lifetime trauma exposure and 33% meeting diagnostic criteria for PTSD. The primary objective of this study is to evaluate the efficacy of a novel telemedicine-delivered prolonged exposure therapy protocol for improving PE attendance and reducing PTSD symptom severity in individuals with concurrent PTSD and OUD.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a telehealth-delivered version of Prolonged Exposure therapy — an evidence-based PTSD treatment — for people who have both PTSD and opioid use disorder (OUD) and are currently on medication-assisted treatment (methadone or buprenorphine). **You may be eligible if...** - You are 18 or older - You have a current PTSD diagnosis - You have been on a stable dose of methadone or buprenorphine for at least 1 month - If you take psychiatric medications, they have been stable for at least 1 month **You may NOT be eligible if...** - You have active psychosis, unstable bipolar disorder, or are at imminent risk for suicide - You have significant cognitive impairment - You are already enrolled in another evidence-based PTSD treatment - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALProlonged exposure therapy

Twelve weekly 60-minute telemedicine-delivered prolonged exposure therapy sessions provided by therapists trained in prolonged exposure therapy.

BEHAVIORALFinancial incentives

Financial incentives contingent upon completion of prolonged exposure therapy sessions

BEHAVIORALTreatment as usual

Continued standard buprenorphine or methadone maintenance treatment from current treatment provider.

Locations(1)

University of Vemont

Burlington, Vermont, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06288711

Related Trials

Randomized Trial of ACT and a Care Management App in Primary Care-based Buprenorphine Treatment

NCT050395541 location

Development of an mHealth Behavioral Sleep Medicine Intervention for Use During Medication Assisted Treatment for MOUD

NCT061578401 location